Skip to content

Search

Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué

Develop a 'roadmap' of key actions that need to be taken by governments to eliminate ARF and eradicate RHD in Africa

Treating trade: the case for clinical engagement with regional trade agreements

The global burden of non-communicable diseases (NCDs) continues to grow. Although developing settings face fastest growth in incidence, no country is exempt.

Supply of benzathine penicillin G: the 20-year experience in Australia

Reliable supplies of BPG are essential for delivering the recommended schedule of secondary prophylaxis for people living with RHD.

Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial

This study assessed the efficacy of seasonal IIV3s against influenza due to 2008 and 2009 seasonal influenza strains and against the 2009 pandemic H1N1 strain

Improving cardiovascular outcomes among Aboriginal Australians: Lessons from research for primary care

Primary care practitioners have an important role in improving Aboriginal cardiovascular care outcomes

Genetic Manipulation of Group A Streptococcus-Gene Deletion by Allelic Replacement

An optimized, rapid method for creating markerless isogenic mutations that combines Gibson assembly cloning with a new temperature-sensitive plasmid, pLZts

Progress towards a coordinated, national paediatric antimicrobial resistance surveillance programme

These data support that children are not just 'little adults' in the AMR era, and analyses by age group are important to detect differences in antibiotic susceptibility

Rheumatic heart disease in pregnancy: Profile of women admitted to a Western Australian tertiary obstetric hospital

This retrospective study assessed maternal and perinatal outcomes for women with rheumatic heart disease admitted to the largest tertiary obstetric hospital

A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease

Few children and adolescents receiving BPG as secondary prophylaxis will achieve concentrations >0.02 mg/L for the majority of the time between injections